The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Alenikova O.A.

Republican Scientific and Practical Center of Neurology and Neurosurgery

Visual hallucinations in Parkinson’s disease

Authors:

Alenikova O.A.

More about the authors

Read: 8130 times


To cite this article:

Alenikova OA. Visual hallucinations in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(6):106‑113. (In Russ.)
https://doi.org/10.17116/jnevro2021121061106

Recommended articles:
Diagnosis and treatment approaches for sialorrhea in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):29-34
Neurochemical mechanisms of tremor in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):64-72
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Bladder dysfunction in patients with stages I—III of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):91-99
A portrait of a doctor with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):160-164
Pathomorphosis of the Parkinson’s disease against the background of DBS STN. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):21-27
Neuroinflammatory and neurodegenerative aspe­cts of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):102-111

References:

  1. Zal’yalova ZA, YAkovleva LA, Bogdanov EI. Nemotornye proyavleniya bolezni Parkinsona. Kazan’: KGMU; 2009. (In Russ.).
  2. Nodel’ MR, YAhno NN. Nedvigatel’nye proyavleniya bolezni Parkinsona i ih vliyanie na kachestvo zhizni. V kn.: Bolezn’ Parkinsona i rasstrojstva dvizhenij. M.: Nauchnyj centr nevrologii; 2008. (In Russ.).
  3. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. The Lancet. Neurology. 2006;5(3):235-245.  https://doi.org/10.1016/S1474-4422(06)70373-8
  4. Fénelon G, Mahieux F, Houn R, Ziégler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain. 2000;123(Pt 4):733-745.  https://doi.org/10.1093/brain/123.4.733
  5. Diederich NJ, Fénelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson’s disease. Nature Reviews. Neurology. 2009;5(6):331-342.  https://doi.org/10.1038/nrneurol.2009.62
  6. Aarsland D, Larsen JP, Tandbert E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. Journal of the American Geriatrics Society. 2000;48(8):938-942.  https://doi.org/10.1111/j.1532-5415.2000.tb06891.x
  7. Janzen J, van’t Ent D, Lemstra AW, Berendse HW, Barkhof F, Foncke EMJ. The pedunculopontine nucleus is related to visual hallucinations in Parkinson’s Disease: preliminary results of a voxel-based morphometry study. Journal of Neurology. 2012;259(1):147-154.  https://doi.org/10.1007/s00415-011-6149-z
  8. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Movement Disorders. 2008;23(6):837-844.  https://doi.org/10.1002/mds.21956
  9. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long term drug therapy. The American Journal of Psychiatry. 1982;139(4):494-497.  https://doi.org/10.1176/ajp.139.4.494
  10. Rondot P, De Recondo J, Coignet A, Ziegler M. Mental disorder in Parkinson’s disease after treatment with L-dopa. Advances in Neurology. 1984;40:259-269. 
  11. Okada K, Suyama N, Oguro H, Yamaguchi S, Kobayashi S. Medication-induced hallucination and cerebral bloodflow in Parkinson’s disease. Journal of Neurology. 1999;246(5):365-368.  https://doi.org/10.1007/s004150050364
  12. Papapetropoulos S, Argyriou AA, Ellul J. Factors associated with drug-induced visual hallucinations in Parkinson’s disease. Journal of Neurology. 2005;252(10):1223-1228. https://doi.org/10.1007/s00415-005-0840-x
  13. Onofrj M, Taylor JP, Monaco D, Franciotti R, Anzellotti F, Bonanni L, Onofrj V, Thomas A. Visual hallucinations in PD and Lewy body dementias: old and new hypotheses. Behavioural Neurology. 2013;27(4):479-493.  https://doi.org/10.3233/BEN-129022
  14. Fénelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006;66(1):93-98.  https://doi.org/10.1212/01.wnl.0000191325.31068.c4
  15. Merims D, Shabtai H, Korczyn AD, Peretz C, Weizman N, Giladi N. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease. Journal of Neural Transmission. 2004;111(10-11):1447-1453. https://doi.org/10.1007/s00702-004-0209-9
  16. Teeple RC, Caplan JP, Stern TA. Visual hallucinations: differential diagnosis and treatment. Primary Care Companion to the Journal of Clinical Psychiatry. 2009;11(1):26-32.  https://doi.org/10.4088/pcc.08r00673
  17. Antal A, Bandini F, Kéri S, Bodis-Wollner I. Visuo-cognitive dysfunctions in Parkinson’s disease. Clinical Neuroscience. 1998;5(2):147-152. 
  18. Barnes J, David AS. Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. Journal of Neurology, Neurosurgery, and Psychiatry. 2001;70(6):727-733.  https://doi.org/10.1136/jnnp.70.6.727
  19. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113-1124. https://doi.org/10.1212/wnl.47.5.1113
  20. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. The Lancet. Neurology. 2009;8(12):1150-1157. https://doi.org/10.1016/S1474-4422(09)70238-8
  21. Hepp DH, Vergoossen DL, Huisman E, Lemstra AW, Berendse HW, Rozemuller AJ, Foncke EM, van de Berg WD. Distribution and load of amyloid-β pathology in Parkinson disease and dementia with lewy bodies. Journal of Neuropathology & Experimental Neurology. 2016;75(10):936-945.  https://doi.org/10.1093/jnen/nlw070
  22. Chan D, Rossor MN. «-But who is that on the other side of you?» Extracampine hallucinations revisited. Lancet. 2002;360(9350):2064-2066. https://doi.org/10.1016/S0140-6736(02)11998-2
  23. Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, Aarsland D. The psychosis spectrum in Parkinson disease. Nature reviews. Neurology. 2017;13(2):81-95.  https://doi.org/10.1038/nrneurol.2016.200
  24. Burke W. The neural basis of Charles Bonnet hallucinations: a hypothesis. Journal of Neurology, Neurosurgery, and Psychiatry. 2002;73(5):535-541.  https://doi.org/10.1136/jnnp.73.5.535
  25. Vaphiades MS, Celesia GG, Brigell MG. Positive spontaneous visual phenomena limited to the hemianopic field in lesions of central visual pathways. Neurology. 1996;47(2):408-417.  https://doi.org/10.1212/wnl.47.2.408
  26. Pang L. Hallucinations experienced by visually impaired: Charles Bonnet Syndrome. Optometry and Vision Science. 2016;93(12):1466-1478. https://doi.org/10.1097/OPX.0000000000000959
  27. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. The retina in Parkinson`s disease. Brain. 2009;132(Pt 5):1128-1145. https://doi.org/10.1093/brain/awp068
  28. Birch J, Kolle RU, Kunkel M, Paulus W, Upadhyay P. Acquired color deficiency in patients with Parkinson’s disease. Vision Research. 1998;38(21):3421-3426. https://doi.org/10.1016/s0042-6989(97)00398-2
  29. Pieri V, Diederich NJ, Raman R, Goetz CG. Decreased color discrimination and contrast sensitivity in Parkinson’s disease. Journal of the Neurological Sciences. 2000;172(1):7-11.  https://doi.org/10.1016/s0022-510x(99)00204-x
  30. Diederich NJ., Raman R, Leurgans S, Goetz CG. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Archives of Neurology. 2002;59(8):1249-1252. https://doi.org/10.1001/archneur.59.8.1249
  31. Alenikova OA, Likhachev SA, Davydova OI. Clinical relevance and pathogenesis of visual disturbances in patients with Parkinson’s disease (literature review). Nevrologicheskij Zhurnal. 2015;20(3):4-10 (In Russ.).
  32. Alenikova OA, Likhachev SA. Diagnostic significance of research contrast sensitivity in patients with Parkinson’s disease and multiple system atrophy. Nevrologiya i Nejrohirurgiya. Vostochnaya Evropa. 2016;6(2):228-236. (In Russ.).
  33. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. The Lancet Neurology. 2006;5(3):235-245.  https://doi.org/10.1016/S1474-4422(06)70373-8
  34. Matsui H, Udaka F, Tamura A, Oda M, Kubori T, Nishinaka K, Kameyama M. The relation between visual hallucinations and visual evoked potential in Parkinson’s disease. Clinical Neuropharmacology. 2005;28(2):79-82.  https://doi.org/10.1097/01.wnf.0000157066.50948.65
  35. Armstrong RA. Visual symptoms in Parkinson’s disease. Parkinson’s Disease. 2011;2011:908306. https://doi.org/10.4061/2011/908306
  36. Quigley HA. Neuronal death in glaucoma. Progress in Retinal and Eye Research. 1999;18(1):39-57.  https://doi.org/10.1016/s1350-9462(98)00014-7
  37. Yoonessi A, Yoonessi A. Functional assessment of magno, parvo and konio-cellular pathways; Current state and future clinical applications. Journal of Ophthalmic & Vision Research. 2011;6(2):119-126. 
  38. Silva MF, Faria P, Regateiro FS, Forjaz V, Januario C, Freire A, Castelo-Branco M. Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson’s disease. Brain. 2005;128(Pt 10):2260-2271. https://doi.org/10.1093/brain/awh581
  39. Blom JD. Defining and measuring hallucinations and their consequences — what is really the difference between a veridical perception and a hallucination? Categories of hallucinatory experiences. In: Collerton D., Mosimann U.P., Perry E., eds. The Neuroscience of Visual Hallucinations. Chichester: John Wiley & Sons; 2015:23-45.  https://doi.org/10.1002/9781118892794.ch2
  40. Grigoreva VN, Slepenyuk AV, Chadaeva OI. Visual hallucinations in acute ischemic stroke. Nevrologicheskij Zhurnal. 2016;21(2):74-81. (In Russ.).
  41. Müri RM. Thalamic and brainstem regulatory systems — why disturbances external to the visual system can cause hallucinations. In: Collerton D, Mosimann UP, Perry E, eds. The Neuroscience of Visual Hallucinations. Chichester: John Wiley & Sons; 2015. https://doi.org/10.1002/9781118892794.ch11
  42. Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson’s disease. Brain. 2000;123(Pt 9):1767-1783. https://doi.org/10.1093/brain/123.9.1767
  43. Janzen J, van ‘t Ent D, Lemstra, AW, Berendse HW, Barkhof F, Foncke EM. The pedunculopontine nucleus is related to visual hallucinations in Parkinson’s disease: preliminary results of a voxel-based morphometry study. Journal of Neurology. 2012;259(1):147-154.  https://doi.org/10.1007/s00415-011-6149-z
  44. Boeve BF, Silber MH, Saper CB, Ferman TJ, Dickson DW, Parisi JE, Benarroch EE, Ahlskog JE, Smith GE, Caselli RC, Tippman-Peikert M, Olson EJ, Lin SC, Young T, Wszolek Z, Schenck CH, Mahowald MW, Castillo PR, Del Tredici K, Braak H. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain. 2007;130(Pt 11):2770-2788. https://doi.org/10.1093/brain/awm056
  45. Manford M, Andermann F. Complex visual hallucinations. Clinical and neurobiological insights. Brain. 1998;121(Pt 10):1819-1840. https://doi.org/10.1093/brain/121.10.1819
  46. Arnulf I, Bonnet AM, Damier P, Bejjani BP, Seilhean D, Derenne JP, Agid Y. Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis. Neurology. 2000;55(2):281-288.  https://doi.org/10.1212/wnl.55.2.281
  47. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson’s disease patients with treatment- induced hallucinations. Annals of Neurology. 1993;34(5):710-714.  https://doi.org/10.1002/ana.410340514
  48. Barnes J. Neuropsychological approaches to understanding visual hallucinations. In: Collerton D., Mosimann U.P., Perry E., eds. The Neuroscience of Visual Hallucinations. Chichester: John Wiley & Sons; 2015. https://doi.org/10.1002/9781118892794.ch9
  49. Diederich NJ, Goetz CG, Stebbins GT. The pathology of hallucinations: one or several points of processing breakdown? In: Collerton D., Mosimann U.P., Perry E., eds. The Neuroscience of Visual Hallucinations. Chichester: John Wiley & Sons; 2015. https://doi.org/10.1002/9781118892794.ch12
  50. Benke T. Peduncular hallucinosis: a syndrome of impaired reality monitoring. Journal of Neurology. 2006;253(12):1561-1571. https://doi.org/10.1007/s00415-0060-0254-4
  51. Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson’s disease. Brain. 2000;123(Pt 9):1767-1783. https://doi.org/10.1093/brain/123.9.1767
  52. Perry EK, Perry RH. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain and Cognition. 1995;28(3):240-258.  https://doi.org/10.1006/brcg.1995.1255
  53. Shine JM, Halliday GM, Naismith SL, Lewis SJ. Visual misperceptions and hallucinations in Parkinson’s disease: dysfunction of attentional control networks? Movement Disorders. 2011;26(12):2154-2159. https://doi.org/10.1002/mds.23896
  54. Aleman A, Vercammen A. The «Bottom-Up» and «Top-Down» Components of the Hallucinatory Phenomenon. In: Jardri R, Cachia A, Thomas P, Pins D, eds. The Neuroscience of Hallucinations. New York, NY: Springer Science Business Media; 2013. https://doi.org/10.1007/978-1-4614-4121-2_6
  55. Collerton D, Perry E., McKeith I. Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations. The Behavioral and Brain Sciences. 2005;28(6):737-757.  https://doi.org/10.1017/S0140525X05000130
  56. Onofrj M, Bonanni L, Albani G, Mauro A, Bulla D, Thomas A. Visual hallucinations in Parkinson’s disease: clues to separate origins. Journal of the Neurological Sciences. 2006;248(1-2):143-150.  https://doi.org/10.1016/j.jns.2006.05.025
  57. Lugaresi E, Provini F, Cortelli P. Agrypnia excitata. Sleep Medicine. 2011;12(suppl 2):3-10.  https://doi.org/10.1016/j.sleep.2011.10.004
  58. Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson’s disease. Movement Disorders. 2003;18(7):831-832.  https://doi.org/10.1002/mds.10450
  59. Taylor JP, Firbank M, Barnett N, Pearce S, Livingstone A, Mosimann U, Eyre J, McKeith IG, O’Brien JT. Visual hallucinations in dementia with Lewy bodies: transcranial magnetic stimulation study. The British Journal of Psychiatry. 2011;199(6):492-500.  ttps://doi.org/10.1192/bjp.bp.110.090373
  60. Goldman JG, Stebbins GT, Dinh V, Bernard B, Merkitch D, deToledo-Morrell L, Goetz CG. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson’s disease with hallucinations. Brain. 2014;137(Pt 3):849-859.  https://doi.org/10.1093/brain/awt360
  61. Collerton D, Mosimann UP, Archibald N. Disorders of visual perception in parkinson’s disease and other lewy body disorders. In: Ebmeier KP, O’Brien JT, Taylor J-P, eds. Psychiatry of Parkinson’s Disease. Adv Biol Psychiatry. Basel: Karger; 2012;27:41-52.  https://doi.org/10.1159/000331525
  62. Mito Y, Yoshida K, Yabe I, Makino K, Tashiro K, Kikuchi S, Sasaki H. Brain SPECT analysis by 3D-SSP and phenotype of Parkinson’s disease. Journal of the Neurological Sciences. 2006;241(1-2):67-72.  https://doi.org/10.1016/j.jns.2005.10.017
  63. O’Brien JT, Firbank MJ, Mosimann UP, Burn DJ, McKeith IG. Change in perfusion, hallucinations and fluctuations in consciousness in dementia with Lewy bodies. Psychiatry Research. 2005;139(2):79-88.  https://doi.org/10.1016/j.pscychresns.2005.04.002
  64. Arnulf I, Bonnet AM, Damier P, Bejjani BP, Seilhean D, Derenne JP, Agid Y. Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis. Neurology. 2000;55(2):281-288.  https://doi.org/10.1212/wnl.55.2.281
  65. Devos D, Kroumova M, Bordet R, Vodougnon H, Guieu JD, Libersa C, Destee A. Heart rate variability and Parkinson’s disease severity. Journal of Neural Transmission. 2003;110(9):997-1011. https://doi.org/10.1007/s00702-003-0016-8
  66. Comella CL. Sleep disorders in Parkinson’s disease: an overview. Movement Disorders. 2007;22(suppl 17):367-373.  https://doi.org/10.1002/mds.21682
  67. Porter B, Macfarlane R, Walker R. The frequency and nature of sleep disorders in a community-based population of patients with Parkinson’s disease. European Journal of Neurology. 2008;15(1):50-54.  https://doi.org/10.1111/j.1468-1331.2007.01998.x
  68. Struck LK, Rodnitzky RL, Dobson JK. Circadian fluctuations of contrast sensitivity in Parkinson’s disease. Neurology. 1990;40(3 Pt 1):467-470.  https://doi.org/10.1212/wnl.40.3_part_1.467
  69. Wright KP, Lowry CA, Lebourgeois MK. Circadian and wakefulness-sleep modulation of cognition in humans. Frontiers in Molecular Neuroscience. 2012;5:50.  https://doi.org/10.3389/fnmol.2012.00050
  70. Korshunov KS, Blakemore LJ, Trombley PQ. Dopamine: a modulator of circadian rhythms in the central nervous system. Frontiers in Cellular Neuroscience. 2017;11:91.  https://doi.org/10.3389/fncel.2017.00091
  71. Mack JM, Schamne MG, Sampaio TB, Pértile RA, Fernandes PA, Markus RP, Prediger RD. Melatoninergic system in parkinson’s disease: from neuroprotection to the management of motor and nonmotor symptoms. Oxidative Medicine and Cellular Longevity. 2016;2016:3472032. https://doi.org/10.1155/2016/3472032
  72. Videnovic A, Golombek D. Circadian dysregulation in Parkinson’s disease. Neurobiology of Sleep and Circadian Rhythms. 2017;2:53-58.  https://doi.org/10.1016/j.nbscr.2016.11.001
  73. Levin YaI. Melatonin i nevrologiya. Russkij Medicinskij Zhurnal. 2007;15(24):1851-1854. (In Russ.).
  74. Schmidt TM, Chen S, Hattar S. Intrinsically photosensitive retinal ganglion cells: many subtypes, diverse functions. Trends in Neurosciences. 2011;34(11):572-580.  https://doi.org/10.1016/j.tins.2011.07.001
  75. Whitehead DL, Davies ADM, Playfer JR, Turnbull CJ. Circadian rest-activity rhythm is altered in Parkinson’s disease patients with hallucinations. Movement Disorders. 2008;23(8):1137-1145. https://doi.org/10.1002/mds.22057
  76. Alenikova O, Likhchev S, Buniak A, Liashkovich M. Daily variability of non-motor symptoms as a reflection of circadian dysregulation in Parkinson’s disease. Movement Disorders. 2019;34(suppl 2):622-623. 

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.